Key facts
- It has raised $38.6M; the latest was Later Stage VC ($230K) in Aug 2024.
- Notable investors include United States Department of War, Agility Labs, Button Capital, Naveen Jain, P4 Precision — 8 tracked in total.
- Flow Pharma has filed 3 Form Ds with the SEC since 2022, most recently Aug 2024 ($225K sold to 3 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Flow Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Flow Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Flow Pharma
Developer of an immunotherapy platform designed to offer curative intervention in cancer and viral disease. The company's platform uses artificial intelligence to create, detect, synthesize, and deliver identical peptides to stimulate therapeutic attacks by the patient's native immune system, enabling patients to have medicines that treat and prevent disease via selective T-cell stimulation.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 1999
- Employees
- 5
- Website
- flowpharma.com/
- Ownership
- Privately Held (backing)
Flow Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Flow Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Flow Pharma in its N-PORT filings yet. We sweep new filings monthly.